More Company News

Avacta

US Orphan Drug designation for AVA6000
05 Sep 2022Read More

Avacta

AVA6000 Phase I moves to fourth cohort
01 Sep 2022Read More

Avacta

AffyXell completes funding round
21 Jul 2022Read More

Avacta

LG Chem licence renewal triggers payment
30 Jun 2022Read More

Avacta

Second dose escalation in AVA6000 Phase I
29 Jun 2022Read More

Avacta

AffyXell expands partnership with GenScript ProBio
16 May 2022Read More

Avacta

London Therapeutics HQ established
11 May 2022Read More

Avacta

AffyXell JV milestone and increased equity stake
13 Apr 2022Read More

Avacta

AVA6000 poster presented at AACR
12 Apr 2022Read More

Avacta

AffyXell JV partners with Biocytogen and KNTSC
08 Apr 2022Read More

1 2 3
Return to Avacta
© 2019-22 Trinity Delta. All rights reserved. Trinity Delta is regulated by the Financial Conduct Authority (Reference number: 725161).